Leica Microsystems | GenomeWeb

Leica Microsystems

Leica Biosystems aims to create a companion test for seribantumab, an investigational human monoclonal antibody used in combination therapy to treat cancer.

The companies plan to combine ACD's RNAscope in situ hybridization assays with Leica's clinical advanced staining instruments to develop tissue-based diagnostics.

Affymetrix this week reported a slight uptick in its second-quarter revenues, which increased 3 percent to $66.4 million from $64.7 million in the year-ago period, beating the average analyst estimate of $65.6 million.

NEW YORK (GenomeWeb News) – Affymetrix and Leica Microsystems today announced a deal to automate Affymetrix's QuantiGene View RNA ISH Tissue Assay on the Leica Bond RX staining platform for research applications.

BG Medicine this week appointed Eric Bouvier as president and CEO. He replaces Pieter Muntendam, who has moved to the role of executive vice president and chief medical officer.

The alliance will combine Leica's automated confocal instruments with Definiens' analysis software.

Abbott's PathVysion FISH assay will be used to develop the test on Leica's BOND platform.

Genetix will operate as a separate business unit within Danaher subsidiary Leica Microsystems.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.